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To determine the presence of Kaposi sarcoma–associ-
ated herpesvirus (KSHV) and other serologic markers, we 
tested serum specimens of 339 Amerindians, 181 rural non-
Amerindians, and 1,133 urban blood donors (13 Amerindi-
ans) in the Brazilian Amazon. High KSHV seroprevalence 
in children and inverse association with herpes simplex vi-
rus type 2 indicates predominant nonsexual transmission 
among Amerindians.
Kaposi sarcoma–associated herpesvirus (KSHV) is the cause of Kaposi sarcoma (KS) and certain lymphopro-
liferative diseases (1). KSHV seroprevalence is low (<5%) 
in most Western populations (1) and reaches 50% in some 
African populations (2), mirroring KS incidence rates (3). 
However, the highest KSHV seroprevalences worldwide 
(>80% in adults) have been reported in Amerindian tribes 
from the Amazon regions of Brazil (4,5) and Ecuador (6), 
despite the apparently low KS incidence in these popula-
tions (7). KSHV is thought to be transmitted through saliva 
between young siblings in disease-endemic areas such as 
French Guiana (8) or Africa (9), whereas sexual transmis-
sion in low-prevalence countries occurs within risk groups 
such as men who have sex with men (10). Modes of trans-
mission have not been clearly determined in Amerindian 
populations.
The Study
We conducted a cross-sectional study during Febru-
ary 2003–April 2004 to investigate the seroprevalence and 
factors associated with KSHV infection in Amerindian and 
non-Amerindian populations living in 2 regions of the Bra-
zilian Amazon: a remote rural region of Para State (Mapu-
era, on the banks of the Trombetas River) and Manaus, the 
capital city of Amazonas State (Figure). Serologic mark-
ers of fecal–oral (hepatitis A virus [HAV]), blood-borne 
(hepatitis B and C viruses [HBV, HCV]) and sexually 
transmitted infections (Treponema pallidum [syphilis] and 
herpes simplex virus type 2 [HSV-2]) were used as proxies 
to identify possible routes of KSHV transmission in these 
populations.
A convenience sample of unselected Amerindians and 
non-Amerindians living in the Mapuera area and a con-
secutive sample of nonpaid fi rst-time blood donors from 
the Manaus blood bank (HemoAm) consented to collection 
of blood samples, as previously reported (4,11) Ethical ap-
proval was obtained from the institutional review board of 
HemoAm, the ethical board of the Brazilian Ministry of 
Health, and the ethics committee of the London School of 
Hygiene and Tropical Medicine.
In the absence of a defi nitive test to determine KSHV 
infection, all serum specimens were tested by using a pre-
viously validated in-house whole-virus KSHV ELISA (12) 
and 2 immunofl uorescence assays (IFAs) that detected an-
tibodies against lytic (IFA-lytic) and latent-associated nu-
clear antigens (IFA-LANA) (12). KSHV infection was de-
fi ned as positivity by any of these serologic assays. Serum 
specimens were also tested for the agent of syphilis by us-
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 4, April 2009 663 
Author affi liations: Universidade de São Paulo, São Paulo, Brazil 
(M.C. Nascimento, L.M. Sumita, V.U. Souza, J. Oliveira, M. Mas-
cheretti, M. Quiroga, R.A.R. Vela, E. Sabino, C.S. Pannuti); and 
London School of Hygiene and Tropical Medicine, London, UK 
(M.C. Nascimento, H.A. Weiss, P. Mayaud)
DOI: 10.3201/eid1504.081488
Figure. Map of Brazil showing study area (black box) in Amazonas 
(Manaus) and Para (Mapeura region) States. Printed with 
permission of the Instituto Brasileiro de Geografi a e Estatística. 
ing a T. pallidum–specifi c assay (Enzygnost Syphilis; Dade 
Behring, Marburg, Germany); for HSV-2 antibodies by us-
ing the type-specifi c HerpeSelect gG2 ELISA (Focus Tech-
nologies, Cypress Hill, CA, USA), with a higher cut-off 
(>3.5) to increase specifi city (13); and for HAV antibodies 
by using BioELISA HAV (Biokit, Barcelona, Spain). Pres-
ence of HBV anti-core antibodies was determined by using 
Ortho HBc ELISA (Ortho Diagnostics, Raritan, NJ, USA) 
in Mapuera serum specimens and Hepanostika anti-HBc 
Uni-Form (Organon-Teknika, Boxtel, the Netherlands) in 
Manaus serum specimens. HCV antibodies were detected 
by using Ortho HCV 3.0 ELISA (Ortho Diagnostics) in 
Mapuera serum specimens and Murex Anti-HCV version 
4.0 ELISA (Murex Biotech S.A., Kyalami, South Africa) 
in Manaus serum specimens.
KSHV seroprevalence was calculated separately for men 
and women and directly age-standardized to the Mapuera 
Amerindian population. The risk associated with KSHV in-
fection was estimated with prevalence ratios (PRs) and 95% 
confi dence intervals (CIs), adjusted for sex and age group 
(18–24 years, 25–34 years, and >35 years for the blood do-
nor population; 0–9 years, 10–17 years, 18–24 years, 25–34 
years, and >35 years for both Mapuera populations). The as-
sociations of KSHV with sociodemographic variables, indi-
cators of socioeconomic status, and other serologic markers 
were estimated with odds ratios (ORs) and 95% CIs. Vari-
ables associated with a signifi cant increased risk for KSHV 
(p<0.05) in univariable analysis were included in a multi-
variable logistic regression model adjusted for age and sex.
We recruited 339 Amerindians (median age 22 years, 
interquartile range [IQR] 13–37 years; 57.5% female) and 
181 non-Amerindians (median age 17 years, IQR 9–35 
years; 58.6% female) in the Mapuera communities and 
1,133 blood donors (median age 25 years, IQR 21–32 years; 
22.9% female) in Manaus. The blood donor population had 
a similar age distribution to that of the adult population in 
Manaus in the 2000 regional census (14).
Among Mapuera Amerindians, KSHV seroprevalence 
was 65.0% in those 0–9 years, increasing to 92.9% in those 
>35 years. In contrast, among Mapuera non-Amerindians, 
KSHV seroprevalence was 9.8% in those 0–9 years of age, 
increasing to 50.0% in those >35 years of age. Among blood 
donors, KSHV seroprevalence was 31.3% in those >35 
years of age and 53.8% in the 13 who were of Amerindian 
descent. After age standardization, KSHV seroprevalence 
remained lower among Mapuera non-Amerindians (30% 
and 27% among men and women, respectively) and blood 
donors (16% and 23%, respectively) than among Mapuera 
Amerindians. When results were compared with those of the 
Mapuera Amerindians, the age-and sex-adjusted PRs were 
0.35 (95% CI 0.28–0.45) and 0.59 (95% CI  0.56–0.63) in 
Mapuera non-Amerindians and blood donors, respectively.
In each population, KSHV seroprevalence was slightly 
higher among females, and increased with age (p for trend 
<0.001) in Mapuera Amerindians and non-Amerindians, 
but not among (adult) blood donors (Table 1). KSHV se-
roprevalence varied little with house crowding (socioeco-
nomic indicator), and hepatitis infections, but was associat-
ed with HSV-2 infection in non-Amerindians (OR 4.2, 95% 
CI 2.1–8.5) and blood donors (OR 1.3, 95% CI 1.0–1.7). 
In Amerindians, KSHV infection was not associated with 
HSV-2 in univariable analysis (OR 0.7, 95% CI 0.3–1.9).
In multivariable analysis (Table 2), KSHV infection 
remained associated with female sex among blood donors 
(age- and sex-adjusted OR [aOR] 1.3, 95% CI 1.0–1.7), 
and increased signifi cantly with age in both Mapuera popu-
lations (p for trend <0.001). KSHV infection was associ-
ated with HSV-2 infection among Mapuera non-Amerindi-
ans (aOR 2.7, 95% CI 1.2–6.5) and Manaus blood donors 
(aOR 1.3, 95% CI 1.0–1.6), but was inversely associated 
with HSV-2 infection in Mapuera Amerindians (aOR 0.3, 
95% CI 0.1–0.9).
Conclusions
Our data confi rm the high KSHV seroprevalence ob-
served among Amazonian Amerindian populations (5,7). 
However, the inclusion of convenience samples of remote 
populations and fi rst-time blood donors, who may not nec-
essarily be representative of the adult general population 
and notably exclude persons who report a range of poten-
tially high-risk behavior for sexually transmitted and blood-
borne infections, may have limited the generalizibility of 
our fi ndings. High KSHV seroprevalence combined with 
an apparent lack of KS development among Amerindian 
populations support the theory of genetic predisposition to 
KSHV acquisition, as hypothesized for other Amazonian 
populations, in whom segregation genetic analysis has sug-
gested that an unidentifi ed recessive gene may infl uence 
KSHV serostatus (15).
The high KSHV seroprevalence (65%) among Mapu-
era Amerindians <10 years of age contrasts with the low 
(9.8%) seroprevalence among non-Amerindians of the 
same age group living in the same area, which suggests 
different transmission modes in these neighboring popula-
tions. Although we did not collect data on the age of initial 
sexual experience in either population, the high prevalence 
in childhood and inverse association with HSV-2 supports 
nonsexual transmission of KSHV in Amerindians. Con-
versely, the association of KSHV infection with HSV-2 
among Mapuera non-Amerindians and blood donors sup-
ports a role for sexual transmission in these groups, al-
though saliva transmission in younger urban inhabitants 
cannot be ruled out. Universal HAV infection status and 
low rates of HBV and HCV in all populations precluded 
any meaningful analysis of transmission routes associated 
with hepatitis viruses.
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In summary, this study contributes data on the epidemi-
ology of KSHV infection and transmission in some Brazil-
ian Amazonian populations. Irrespective of urban or rural 
setting, our data are consistent with a predominant non-
sexual transmission of KSHV (most likely through saliva) 
in Amerindian tribes compared with a probable combina-
tion of sexual and nonsexual modes of transmission among 
non-Amerindian populations living in the same region.
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Table 1. Seroprevalence of KSHV among 3 populations in the Brazilian Amazon*† 
Mapuera Amerindians, n = 339† Mapuera non-Amerindians, n = 181† Manaus blood donors, n = 1,133† 
Variables
% KSHV positive 
(no. tested) OR (95% CI) 
% KSHV positive 
(no. tested) OR (95% CI) 
% KSHV positive 
(no. tested) OR (95% CI) 
Sex 
 Male 79.2 (144) 1 26.7 (75) 1 28.6 (874) 1
 Female 82.6 (195) 1.2 (0.7–2.1) 27.4 (106) 1.0 (0.5–2.0) 34.4 (259) 1.3 (1.0–1.7) 
 p value 0.4 0.1 0.08
Age group, y
 0–9 65.0 (43) 0.1 (0.05–0.4) 9.8 (51) 0.1 (0.03–0.3) – –
 10–17 70.0 (93) 0.2 (0.07–0.4) 22.5 (40) 0.3 (0.1–0.7) – –
 18–34 86.5 (104) 0.5 (0.2–1.3) 27.3 (44) 0.4 (0.1–0.9) 29.6 (916) 0.9 (0.7–1.3) 
>35 92.9 (99) 1 50.0 (46) 1 31.3 (217) 1
  p for trend <0.001 <0.001
Crowding‡ 
 1–2 93.7 (16) 1 55.6 (9) 1 32.6 (175) 1
 3 91.3 (23) 0.7 (0.06–8.4) 33.3 (15) 0.4 (0.07–2.2) 29.9 (941) 0.9 (0.6–1.2) 
>4 79.7 (300) 0.3 (0.03–2.0) 24.8 (145) 0.3 (0.07–1.3) 6.2 (16) 0.4 (0.2–1.0) 
 p value 0.1 0.1 0.1
Ethnicity 
 African – – – – 29.6 (743) 1
 Caucasian – – – – 30.5 (308) 1.0 (0.8–1.4) 
 Indigenous 100 (339) – – – 53.8 (13 2.8 (0.9–8.3) 
 Other – – 100 (181) – 25.8 (66) 0.8 (0. 5–1.5) 
 p value 0.08
Hepatitis A virus 
 Negative 83.3 (6) 1 12.5 (16) 1 42.9 (7)§ 1
 Positive 81.1 (333) 0.9 (0.1–7.5) 28.5 (165) 2.8 (0.6–12.7) 28.6 (154)§ 0.5 (0.1–2.5) 
 p value 0.9 0.2 0.4
Hepatitis B virus 
 Negative 81.6 (315) 1 32.0 (75)§ 1 30.2 (1,075) 1
 Positive 73.9 (23) 0.6 (0.2–1.7) 53.3 (15)§ 2.4 (0.8–7.5) 25.0 (56) 0.8 (0.4–1.4) 
 p value 0.4 0.1 0.4
Hepatitis C virus
 Negative 81.0 (338) 36.0 (90)† 29.9 (1,129) 1
 Positive 0 0 25.0 (4) 0.8 (0.1–7.5) 
  p value 0.8
HSV-2
 Negative 81.5 (314) 1 18.1 (127) 1 27.8 (715) 1
 Positive 76.0 (25) 0.7 (0.3–1.9) 48.1 (54) 4.2 (2.1–8.5) 33.2 (406) 1.3 (1.0–1.7) 
  p value 0.5 <0.001 0.06
Trepomena pallidum 26.3 (171) 
 Negative 81.0 (338) – 40.0 (10) 1 29.9 (1,122) 1
 Positive 0 1.9 (0.5–6.9) 36.4 (11) 1.2 (0.6–2.3) 
 p value 0.3 0.7
*Seroreactivity by any serologic assay, whole virus. KSHV, Kaposi sarcoma–associated herpesvirus; OR, odds ratio; CI, confidence interval; HSV-2, 
herpes simplex virus type 2. 
†Some figures do not add up to the total because of missing data. 
‡Number of residents living in the house. 
§Only a random subsample tested. 
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Table 2. Multivariable analysis of risk factors for KSHV infection among 3 populations in the Brazilian Amazon* 
aOR (95% CI) 
Variables Mapuera Amerindians, n = 339  Mapuera non-Amerindians, n = 181 Manaus blood donors, n = 1,133 
Sex 
 Male 1 1 1
 Female 1.2 (0.7–2.2) 1.0 (0.5–2.1) 1.3 (1.0–1.7) 
 p value 0.5 0.9 0.08
Age group, y
 0–9 0.1 (0.05–0.4) 0.1 (0.04–0.3) 
 10–17 0.2 (0.07–0.4) 0.3 (0.1–0.7) 
 18–34 0.5 (0.2–1.2) 0.4 (0.1–0.9) 0.9 (0.7–1.3) 
>35 1 1 1
  p value <0.001 <0.001 0.6
HSV-2
 Negative 1 1 1
 Positive 0.3 (0.1–0.9) 2.7 (1.2–6.5) 1.3 (1.0–1.6) 
 p value 0.03 0.02 0.09
*Seroreactivity by any serologic assay (whole virus ELISA, IFA-LANA, or IFA-lytic) in multivariable analysis. KSHV, Kaposi sarcoma–associated 
herpesvirus; IFA-LANA, immunofluorescence assay that detected latent-associated nuclear antigens; IFA-lytic, IFA that detected lytic-associated nuclear 
antigens; aOR, age- and sex-adjusted odds ratio; CI, confidence interval; HSV-2, herpes simplex virus type-2. 
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